Following
on from the last BTLP-TACT exercise, I had a little look on Google to remind
myself…
|
Fresh frozen
plasma (FFP) is recommended for a variety of conditions,
including:
·
Bleeding FFP is used
to prevent or stop bleeding, or to replace coagulation factors in patients
with abnormal coagulation tests. It can be used for patients with: ·
Disseminated
intravascular coagulation (DIC) ·
Bleeding
associated with acute blood loss ·
Bleeding
in patients with decompensated liver disease ·
Warfarin
overdose with life-threatening bleeding · ·
Surgery FFP is used
for patients with abnormal coagulation tests who are undergoing a planned
surgery or invasive procedure.
·
Plasma
exchange FFP is used
for plasma exchange in patients with thrombotic thrombocytopenic purpura
(TTP) or hyperviscosity syndrome.
·
Factor
deficiency FFP is used
to replace coagulation factors in patients with congenital or acquired factor
deficiency.
·
Trauma FFP is used
for trauma patients requiring massive transfusion.
|
Fresh frozen
plasma (FFP) is NOT recommended in the following situations:
·
When
there are more effective treatments FFP is not
recommended when there are more effective treatments for the condition, such
as vitamin K, cryoprecipitate, or factor VIII.
·
When
blood volume can be replaced FFP should
not be used as a volume expander unless there is active bleeding and
coagulation deficiencies. ·
To
reverse anticoagulation FFP should
not be used to reverse anticoagulation caused by heparin, direct thrombin
inhibitors, or direct factor Xa inhibitors. ·
For
disseminated intravascular coagulation FFP is not
recommended for disseminated intravascular coagulation without bleeding. ·
For
vitamin K deficiency FFP should
not be used to reverse vitamin K deficiency for neonates or patients in
intensive care units.
·
For
patients with normal clotting FFP should
not be used for patients who are bleeding due to a surgical cause and who
have normal clotting.
·
As
a circulating volume replacement FFP should
never be used as circulating volume replacement.
|
|
Cryoprecipitate
is recommended for patients who have low levels of
clotting proteins, especially fibrinogen, or who are bleeding or have a risk
of bleeding: ·
Bleeding Cryoprecipitate
can be used to prevent or control bleeding in patients whose blood doesn't
clot properly. ·
Invasive
procedures Cryoprecipitate
can be used before an invasive procedure in patients with significant
hypofibrinogenemia. ·
Massive
transfusions Cryoprecipitate
is often used when a patient needs a large number of blood components at
once.
·
Fibrinogen
deficiency Cryoprecipitate
can be used to treat acquired fibrinogen deficiency or dysfibrinogenaemia. ·
Disseminated
intravascular coagulation (DIC) Cryoprecipitate
can be used to treat DIC.
|
Cryoprecipitate
is NOT recommended for the following conditions:
·
Hemophilia
A Cryoprecipitate
should not be used to treat Hemophilia A unless other factor VIII
preparations are not available. ·
Von
Willebrand disease Cryoprecipitate
should not be used to treat von Willebrand disease unless the patient does
not respond to DDAVP.
·
Factor
XIII deficiency Cryoprecipitate
is not usually given for Factor XIII deficiency because virus-inactivated
concentrates of this protein are available. ·
Congenital
afibrinogenemia or dysfibrinogenemia Cryoprecipitate
should not be used to treat these conditions. ·
Factor
deficiencies Cryoprecipitate
should not be used to treat factor deficiencies when specific factor
concentrates are available
|
